A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

NCT01743950 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

49

Enrollment

OTHER

Sponsor class

Stopped slow accrual

Conditions

Glioma

Interventions

DRUG: Bevacizumab
RADIATION: PRDR

Sponsor

University of Wisconsin, Madison

Collaborators

[object Object]
[object Object]